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Katsunori Ikari*, Koichiro Yano, Shinji Yoshida, Atsuo Taniguchi, Hisashi Yamanaka and Shigeki MomoharaRheumatoid arthritis (RA) is a complex polygenic dis-
ease characterized by progressive joint destruction.
Anti-citrullinated peptide antibody (ACPA) is the most
specific autoantibody for RA. Genetic polymorphisms in
the PADI4 gene, encoding citrullinating enzyme pepti-
dylarginine deiminase 4 (PADI4), have been associated
with susceptibility to RA [1,2]. They have also been re-
ported to be associated with radiographic joint destruction
in patients with RA [3,4]. We focused on ACPA-negative
RA patients to investigate whether a PADI4 polymorph-
ism is associated with joint damage in ACPA-negative
patients.
DNA samples from 122 Japanese ACPA-negative RA
patients were used for the study; 81.1% were female,
51.6% were rheumatoid factor (RF)-positive, and the
mean age was 55 years. Sharp/van der Heijde score of
the hands at a 5-year disease duration, which represents
joint damage, was scored and log-transformed as de-
scribed elsewhere [4]. Single-nucleotide polymorphism
(SNP) rs2240340 was selected and genotyped by using a
TaqMan method as described elsewhere [4]. The genetic
risk of joint damage associated with rs2240340 was
assessed by multiple regression analysis adjusted for
HLA-DRB1 shared-epitope alleles and RF that are
thought to be associated with joint damage in patients
with RA [4].* Correspondence: kikari@twmu.ac.jp
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unless otherwise stated.The PADI4 SNP was significantly associated with
radiographic joint destruction in the ACPA-negative RA
patients in a recessive model (P = 0.0287) (Table 1 and
Figure 1). The overall genotyping success rate was 99.2%
and the genotype concordance rate was 100% as assessed
by duplicate samples. Although the sample size is one of
the major limitations to the study of ACPA-negative
patients because of the high positivity of ACPA (up to
90%) in RA populations, we were able to collect DNA
samples from 122 ACPA-negative RA patients with
radiographic data.
PADI4 encodes citrullinating enzymes that may play
an important role in ACPA formation. It has been
shown that PADI4 alleles were associated with the pres-
ence of ACPA in patients with RA [1]. In the present
study, we have shown that PADI4 polymorphism con-
tributes to joint destruction in ACPA-negative RA pa-
tients. A recent study has suggested that PADI4 gene
contributes to the development of RA, regardless of
ACPA status [3]. We have also reported that the PADI4
risk allele has an impact on joint damage after adjust-
ment for ACPA status [4]. The PADI4 gene is likely to
play a role in the disease progression of RA in addition
to its role in ACPA formation. The results of this study
provide important knowledge of the risks on progressive
joint damage in patients with RA.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Association of PADI4 SNP (recessive model) with
Sharp/van der Heijde score of hands at 5-year disease
duration in ACPA-negative RA patients
Factor Beta (95% CI) P value
rs2240340, PADI4 0.72 (0.08-1.36) 0.0287
HLA-DRB1 SE 0.36 (0.01-0.73) 0.0587
RF 0.54 (0.05-1.02) 0.0316
ACPA, Anti-citrullinated peptide antibody; CI, Confidence interval; PADI4,
Peptidyl arginine deiminase type IV; RA, Rheumatoid arthritis; RF, Rheumatoid
factor; SE, Shared epitope; SNP, Single-nucleotide polymorphism.
Figure 1 Boxplots representing the distribution of Sharp/van
der Heijde score of hands at 5-year disease duration according
to the number of the susceptibility allele of rs2240340 (minor
allele, A) in the PADI4 locus. Each box represents the interquartile
range of values, and the bold line shows the median value. The
vertical lines show maximum and minimum values that fall within
1.5 box lengths, and the open circles show extreme values of more
than 1.5 boxplot lengths. PADI4, peptidylarginine deiminase 4; SHS,
Sharp/van der Heijde score.
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